This new GLP-1 play is on a tear. UBS sees nearly a 50% gain from here
MBX Biosciences has rallied more than 230% over the past year, but there's room for still more upside from current levels, according to UBS.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief